purpose investigate incidence influencing factors acute genitourinary gu gastrointestinal morbidities patients prostate cancer treated proton therapy methods materials total NUMBER patients histologically proven stage prostate cancer treated proton therapy NUMBER NUMBER NUMBER NUMBER received neoadjuvant androgen suppression therapy patients treated protons using techniques dose NUMBER gye histogram analyses performed incidence acute morbidity evaluated using national cancer institute common toxicity criteria version NUMBER clinical factors including age clinical target volume initial antigen level t stage presence diabetes mellitus use androgen suppression therapy investigated determine affected incidence acute gu morbidity results developed grade NUMBER higher acute gastrointestinal morbidity contrast NUMBER NUMBER NUMBER NUMBER patients experienced acute grade NUMBER grade NUMBER gu morbidities respectively NUMBER patients successfully relieved administration selective blocker multivariate analysis showed larger clinical target volume p NUMBER use androgen suppression therapy p NUMBER significant factors prediction acute grade gu morbidity conclusion experience proton therapy low incidence acute gastrointestinal morbidity observed contrast incidence acute gu morbidity similar reports photon radiotherapy additional warranted elucidate safety efficacy proton therapy prostate cancer ct1 t4n0m0 NUMBER NUMBER mev lateral opposed dose volume prostate specific alpha NUMBER NUMBER NUMBER follow long term